Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 100010, China.
Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, 310009, China.
Future Oncol. 2021 Nov;17(33):4571-4582. doi: 10.2217/fon-2021-0435. Epub 2021 Sep 14.
To determine how consistently Chinese glioblastoma multiforme (GBM) patients were treated according to the Stupp regimen. The proportion of treatments conforming to the Stupp regimen and reasons for nonconformity were evaluated in 202 newly diagnosed GBM patients. Only 15.8% of GBM patients received treatments compliant with the Stupp regimen. The main deviations were temozolomide dosages >75 mg/m (58/120; 48.3%) and treatment durations <42 days (84/120; 70.0%) in the concomitant phase and temozolomide dosages <150 mg/m (89/101; 88.1%) in the maintenance phase. Median overall survival (27.09 vs 18.21 months) and progression-free survival (14.27 vs 12.10 months) were longer in patients who received Stupp regimen-compliant treatments. Increased conformity to the Stupp regimen is needed for GBM patients in China.
评估中国胶质母细胞瘤（GBM）患者接受替莫唑胺联合放疗方案的一致性。
对 202 例新诊断的 GBM 患者进行评估，分析其治疗方案是否符合 Stupp 方案以及不符合的原因。
仅有 15.8%的 GBM 患者接受了符合 Stupp 方案的治疗。在同期放化疗阶段，主要的不依从现象为替莫唑胺剂量＞75mg/m²（58/120；48.3%）和治疗时间＜42 天（84/120；70.0%）；在维持治疗阶段，替莫唑胺剂量＜150mg/m²（89/101；88.1%）。接受符合 Stupp 方案治疗的患者中位总生存（27.09 个月比 18.21 个月）和无进展生存（14.27 个月比 12.10 个月）均更长。
中国 GBM 患者需要增加对 Stupp 方案的依从性。
